⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Worcester HIV Vaccine and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Worcester HIV Vaccine
↗Worcester, Massachusetts, USA
Worcester HIV Vaccine (WHV) is a clinical-stage biotechnology company focused on the development of a preventive HIV vaccine. The company utilizes a proprietary polyvalent DNA-prime/protein-boost technology platform, originally developed at the University of Massachusetts Medical School, to target multiple subtypes of HIV-1.
Founded in 2018, WHV aims to address the global HIV epidemic by advancing vaccine candidates through clinical trials. The company's research is heavily rooted in the work of Dr. Shan Lu, a pioneer in nucleic acid vaccines, and focuses on eliciting broad, cross-protective immune responses against diverse circulating HIV strains.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$0-$1M
Founded:2018
Ownership:private
Status:operating
FUNDING
Stage:Pre-IPO
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:DNA Vaccine, Recombinant Protein
Active Trials:1
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:University of Massachusetts Medical School (Licensing/Research), Desmond Tutu Health Foundation (Clinical Trial Site)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Shan Lu - Co-founder and Chief Scientific Officer
Shuying Liu - Director of R&D
Scientific Founders:Shan Lu
LINKS
Website:whvaccine.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Worcester HIV Vaccine. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.